KRAS and neoplasm: Based on preclinical evidence of metabolic pathways altered by oncogenic Kras in PDAC, we hypothesize that L-glutamine supplementation may further alter the metabolic pathways initially reprogrammed by KRAS to sustain tumor proliferation.